ProTrans demonstrates effect at 2 years after repeated treatments
NextCell Pharma AB ("NextCell") today announces that the ProTrans-Repeat trial met its primary safety endpoint. There were no severe adverse events recorded during the 12-month follow-up period after a second dose of ProTrans™ (ProTrans). Furthermore, a strong tendency of sustained efficacy was observed in the three patients receiving high dose ProTrans.· Primary safety endpoint met · Tendency of sustained efficacy observed for high dose patients · 2-year preservation of insulin production significantly higher for patients treated with high dose as compared to low dose ProTrans-